In Vitro and in Vivo Effects of Chitosan-praziquantel and Chitosan-albendazole Nanoparticles on Echinococcus Granulosus Metacestodes

Overview

Journal Parasitol Res

Specialty Parasitology

Date 2018 Apr 5

PMID 29616349

Citations 9

Authors

Negin Torabi

Faramarz Dobakhti

Soghrat Faghihzadeh

Ali Haniloo

Affiliations

Soon will be listed here.

Abstract

Cystic echinococcosis (CE), which is caused by the metacestode of Echinococcus granulosus, is one of the most important zoonoses affecting humans. Benzimidazoles (in particular albendazole) and praziquantel (PZQ) are effective against CE, but poor water solubility of these agents often leads to inadequate results. Here, we evaluate the effects of chitosan-albendazole (ChABZ) and chitosan-praziquantel (ChPZQ) nanoparticles as a new formulation on hydatid cysts both in vitro and in vivo. Developed microcysts in culture were treated with different concentrations of ChABZ and ChPZQ nanoparticles (either alone or in combination), and ABZ + PZQ suspension. The viability rate of microcysts was used to evaluate the drug efficacies. In addition, the prophylactic and therapeutic effects of the drugs were studied on infected DBA/2 mice. Transmission electron microscopy was used to observe the ultra-structural changes. The viability rate of microcysts and differences in cyst weights were compared by ANOVA, and the cyst numbers were compared using the Kruskal-Wallis test. The combination of ChABZ + ChPZQ nanoparticles was more effective than the ABZ + PZQ suspension in vitro (p < 0.05). In prophylaxy, a significant reduction was observed both in size and in number of the cysts in ChABZ + ChPZQ nanoparticle groups compared with the control group (p < 0.05). In the therapeutic stage, however, this treatment only reduced the cyst numbers. Degeneration of the microcysts treated with the drugs was evident in the ultra-structural imaging. Overall, the nanoparticulate drugs were more effective than their suspension counterparts, but further studies are recommended to evaluate the full potential of these nanoparticles in the treatment of human CE.

Citing Articles

Evaluation of the In-Vitro Effects of Albendazole, Mebendazole, and Praziquantel Nanocapsules against Protoscolices of Hydatid Cyst.

Soleymani N, Sadr S, Santucciu C, Rahdar A, Masala G, Borji H Pathogens. 2024; 13(9).

PMID: 39338980 PMC: 11435210. DOI: 10.3390/pathogens13090790.

Assessment of mechanism involved in the apoptotic and anti-cancer activity of Quercetin and Quercetin-loaded chitosan nanoparticles.

Dogan M Med Oncol. 2022; 39(11):176.

PMID: 35999475 DOI: 10.1007/s12032-022-01820-x.

Integrative Analysis of RNA Expression and Regulatory Networks in Mice Liver Infected by .

Liu T, Li H, Li Y, Wang L, Chen G, Pu G Front Cell Dev Biol. 2022; 10:798551.

PMID: 35399512 PMC: 8989267. DOI: 10.3389/fcell.2022.798551.

Chitosan Nanoparticles for Antiviral Drug Delivery: A Novel Route for COVID-19 Treatment.

Safer A, Leporatti S Int J Nanomedicine. 2021; 16:8141-8158.

PMID: 34949922 PMC: 8689047. DOI: 10.2147/IJN.S332385.

Evaluation of Allicin Against Alveolar Echinococcosis In Vitro and in a Mouse Model.

Liu C, Fan H, Guan L, Ma L, Ge R Acta Parasitol. 2021; 67(1):79-93.

PMID: 34143400 PMC: 8938363. DOI: 10.1007/s11686-021-00434-z.

References

Mohamed A, Yasawy M, Al Karawi M . Combined albendazole and praziquantel versus albendazole alone in the treatment of hydatid disease. Hepatogastroenterology. 1998; 45(23):1690-4. View

Daniel-Mwambete K, Torrado S, Cuesta-Bandera C, Ponce-Gordo F, Torrado J . The effect of solubilization on the oral bioavailability of three benzimidazole carbamate drugs. Int J Pharm. 2004; 272(1-2):29-36. DOI: 10.1016/j.ijpharm.2003.11.030. View

Ahmadnia S, Moazeni M, Mohammadi-Samani S, Oryan A . In vivo evaluation of the efficacy of albendazole sulfoxide and albendazole sulfoxide loaded solid lipid nanoparticles against hydatid cyst. Exp Parasitol. 2013; 135(2):314-9. DOI: 10.1016/j.exppara.2013.07.017. View

Moro P, Schantz P . Echinococcosis: a review. Int J Infect Dis. 2008; 13(2):125-33. DOI: 10.1016/j.ijid.2008.03.037. View

Nazligul Y, Kucukazman M, Akbulut S . Role of chemotherapeutic agents in the management of cystic echinococcosis. Int Surg. 2015; 100(1):112-4. PMC: 4301274. DOI: 10.9738/INTSURG-D-14-00068.1. View

Casado N, Rodriguez-Caabeiro F, Hernandez S . In vitro survival of Echinococcus granulosus protoscolices in several media, at +4 degrees C and +37 degrees C. Z Parasitenkd. 1986; 72(2):273-8. DOI: 10.1007/BF00931155. View

Amidon G, Lennernas H, Shah V, Crison J . A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995; 12(3):413-20. DOI: 10.1023/a:1016212804288. View

Casado N, Perez-Serrano J, Denegri G, Rodriguez-Caabeiro F . Development of chemotherapeutic model for the in vitro screening of drugs against Echinoccus granulosus cysts: the effects of an albendazole-albendazole sulphoxide combination. Int J Parasitol. 1996; 26(1):59-65. DOI: 10.1016/0020-7519(95)00095-x. View

Diaz A, Casaravilla C, Allen J, Sim R, Ferreira A . Understanding the laminated layer of larval Echinococcus II: immunology. Trends Parasitol. 2011; 27(6):264-73. DOI: 10.1016/j.pt.2011.01.008. View

10.

Yasawy M, Al Karawi M, Mohamed A . Combination of praziquantel and albendazole in the treatment of hydatid disease. Trop Med Parasitol. 1993; 44(3):192-4. View

11.

Cobo F, Yarnoz C, Sesma B, Fraile P, Aizcorbe M, Trujillo R . Albendazole plus praziquantel versus albendazole alone as a pre-operative treatment in intra-abdominal hydatisosis caused by Echinococcus granulosus. Trop Med Int Health. 1998; 3(6):462-6. DOI: 10.1046/j.1365-3156.1998.00257.x. View

12.

Diaz A, Casaravilla C, Irigoin F, Lin G, Previato J, Ferreira F . Understanding the laminated layer of larval Echinococcus I: structure. Trends Parasitol. 2011; 27(5):204-13. DOI: 10.1016/j.pt.2010.12.012. View

13.

Kang B, Lee S, Ng C, Kim J, Park J . Exploring the Preparation of Albendazole-Loaded Chitosan-Tripolyphosphate Nanoparticles. Materials (Basel). 2017; 8(2):486-498. PMC: 5455285. DOI: 10.3390/ma8020486. View

14.

Pensel P, Castro S, Allemandi D, Bruni S, Palma S, Elissondo M . Enhanced chemoprophylactic and clinical efficacy of albendazole formulated as solid dispersions in experimental cystic echinococcosis. Vet Parasitol. 2014; 203(1-2):80-6. DOI: 10.1016/j.vetpar.2014.01.027. View

15.

Elissondo M, Ceballos L, Dopchiz M, Andresiuk V, Alvarez L, Sanchez Bruni S . In vitro and in vivo effects of flubendazole on Echinococcus granulosus metacestodes. Parasitol Res. 2006; 100(5):1003-9. DOI: 10.1007/s00436-006-0381-y. View

16.

Li X, Min M, Du N, Gu Y, Hode T, Naylor M . Chitin, chitosan, and glycated chitosan regulate immune responses: the novel adjuvants for cancer vaccine. Clin Dev Immunol. 2013; 2013:387023. PMC: 3603646. DOI: 10.1155/2013/387023. View

17.

Richards K, Morris D, Taylor D . Echinococcus multilocularis: ultrastructural effect of in vivo albendazole and praziquantel therapy, singly and in combination. Ann Trop Med Parasitol. 1989; 83(5):479-84. DOI: 10.1080/00034983.1989.11812375. View

18.

Choi B, Jo D, Anower A, Islam S, Sohn S . Chitosan as an Immunomodulating Adjuvant on T-Cells and Antigen-Presenting Cells in Herpes Simplex Virus Type 1 Infection. Mediators Inflamm. 2017; 2016:4374375. PMC: 5209624. DOI: 10.1155/2016/4374375. View

19.

Ogawara K, Yoshida M, Higaki K, Kimura T, Shiraishi K, Nishikawa M . Hepatic uptake of polystyrene microspheres in rats: effect of particle size on intrahepatic distribution. J Control Release. 1999; 59(1):15-22. DOI: 10.1016/s0168-3659(99)00015-2. View

20.

Liang W, Wang X, Wu X, Zhang S, Sun H, Ma X . [Efficacy of albendazole chitosan microspheres against Echinococcus granulosus infection in mice]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2014; 32(3):188-92. View